Recruiting

Testing a new immunotherapy to clear remaining leukemia cells in blood

Plain-English translation of NCT07566364 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a medication called , which works by helping your immune system fight leukemia cells that remain in your body even after other treatments. You would take this medication along with the BTK inhibitor you're already using. The goal is to see if adding this treatment can completely clear the tiny amounts of leukemia cells (called measurable residual disease) that blood tests can still detect.

Many patients with chronic lymphocytic leukemia still have small numbers of cancer cells left in their body even when they're being treated with current medications. Researchers believe this medication might help eliminate those remaining cells completely, which could improve long-term outcomes and possibly allow some patients to stop all treatment eventually.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have chronic lymphocytic leukemia and have already tried at least two other systemic treatments, including your current BTK inhibitor
you have had your leukemia for at least 12 months while on continuous BTK inhibitor therapy
you have detectable residual leukemia cells in your bone marrow that tests can measure
you have high-risk features such as prior disease progression on certain treatments, a specific genetic mutation (TP53 or del(17p)), or unmutated IGHV status
you are in generally good health with adequate kidney, liver, and bone marrow function

You likely don't qualify if…

you have untreated or uncontrolled HIV infection (though stable, well-controlled HIV is okay)
you have a history of AIDS-related infections within the past year
you have significant organ damage or severely low blood cell counts due to causes other than leukemia
you are unable to take contraception if you could become pregnant, or you are pregnant or breastfeeding
you have unresolved side effects from prior treatments (except for hair loss or certain nerve-related side effects)

What participation looks like

You would continue taking your current BTK inhibitor while receiving the new medication as injections given through a vein. During the first cycle (3 weeks), you would come in three times for treatment, then once per cycle afterward. The first cycle may require some inpatient time for dose adjustments, but later doses are given outpatient. You would receive this treatment for 17 cycles (about 12 months), with bone marrow tests and blood tests to monitor how well it's working. After treatment ends, you would have follow-up visits every 6 months for 3 years to track your disease status.

AI-generated summary from trial data · Aug 20, 2026 · Not medical advice

Trial locations(1 site)

United States

UT MD Anderson, Houston, Texas